• In recent weeks, Hims & Hers Health has secured a partnership with Novo Nordisk to offer GLP-1 weight-loss drugs, completed the acquisition of digital health platform Eucalyptus, and appointed Dr. Anant Vinjamoori as Chief Medical Officer, while investors await an FDA Pharmacy Compounding Advisory Committee decision on adding several peptides to the 503A bulk substances list.
• Together, these moves deepen the company’s role in chronic weight management and broaden its telehealth footprint, potentially reshaping how its subscription-based model scales across obesity care and international markets.
• Next, we’ll examine how the Novo Nordisk GLP-1 partnership could alter Hims & Hers’ investment narrative and long-term growth assumptions.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers today, you need to believe its telehealth platform can convert rising demand for weight loss and chronic care into durable, subscription-based revenue, while managing regulatory and execution risks. The Novo Nordisk GLP-1 deal is the key near term catalyst, with the upcoming FDA Pharmacy Compounding Advisory Committee peptide decision a close second. The biggest current risk is that obesity and peptide regulation shifts faster than the business can adjust.

Among the recent updates, the Novo Nordisk partnership stands out as most relevant. It anchors Hims & Hers firmly in FDA approved, branded GLP-1 treatments just as investors focus on the July PCAC meeting on peptides. That combination ties the main upside catalyst to branded obesity drugs, while leaving peptides as a separate, more uncertain layer that could either add incremental opportunity or highlight how dependent the story is on a narrow set of therapies.

Yet even with these positives, investors should be aware that tighter peptide rules or GLP-1 reimbursement changes could...

Hims & Hers Health's narrative projects $3.8 billion revenue and $164.3 million earnings by 2029. This requires 16.6% yearly revenue growth and a $177.5 million earnings increase from -$13.2 million today.

Uncover how Hims & Hers Health's forecasts yield a $26.82 fair value, a 24% downside to its current price.

Exploring Other Perspectives

By contrast, the most pessimistic analysts worry that rising regulation and price pressure could cap upside, even as they still model revenue at about US$3.5 billion and earnings near US$35 million by 2029, so it is worth asking how fresh GLP 1 news and any PCAC outcome might shift those expectations.

Explore 36 other fair value estimates on Hims & Hers Health - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
• Our free Hims & Hers Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Hims & Hers Health's overall financial health at a glance.

No Opportunity In Hims & Hers Health?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• The latest GPUs need a type of rare earth metal called Neodymium and there are only 30 companies in the world exploring or producing it. Find the list for free.
• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.